Guangdong Marubi Biotechnology Co., Ltd.

SHSE:603983 Stock Report

Market Cap: CN¥13.6b

Guangdong Marubi Biotechnology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Huaiqing Sun

Chief executive officer

CN¥2.1m

Total compensation

CEO salary percentagen/a
CEO tenure12.9yrs
CEO ownership72.7%
Management average tenureno data
Board average tenure4.5yrs

Recent management updates

Recent updates

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Dec 25
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Dec 09
Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Nov 22
Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Sep 26
Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Aug 30
Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Jun 19
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

May 29
Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

May 07
Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Mar 27
Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

Feb 29
Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

CEO

Huaiqing Sun (54 yo)

12.9yrs

Tenure

CN¥2,109,000

Compensation

Mr. Huaiqing Sun is Chairman and Chief Executive Officer of Guangdong Marubi Biotechnology Co., Ltd. from January 18, 2012.


Board Members

NamePositionTenureCompensationOwnership
Huaiqing Sun
Chairman & CEO12.9yrsCN¥2.11m72.72%
CN¥ 9.9b
Kaihui Wang
Director & CFOno dataCN¥2.31mno data
Lingchun Zeng
Chief Marketing Officer & Director6.6yrsCN¥2.08mno data
Yong Cao
Independent Director1.6yrsCN¥58.30kno data
Yi Shen
Director3.8yrsCN¥1.04mno data
Chaowan Guo
Director3.8yrsCN¥832.00kno data
Yalin Bi
Independent Director6.6yrsCN¥100.00kno data
Ka Yeung Chan
Supervisor5yrsno datano data
Qingmei Chen
Chairman of the the Supervisory Board4.1yrsno datano data

4.5yrs

Average Tenure

46yo

Average Age

Experienced Board: 603983's board of directors are considered experienced (4.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 02:40
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Marubi Biotechnology Co., Ltd. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei YangCGS International
Jin LiChangjiang Securities Co. LTD.
Lei YangChina Galaxy International Securities (Hong Kong)